Actively Recruiting
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Led by Philip Kern · Updated on 2026-02-03
96
Participants Needed
1
Research Sites
241 weeks
Total Duration
On this page
Sponsors
P
Philip Kern
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
CONDITIONS
Official Title
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hemoglobin A1C between 5.7 and 6.4
- Body mass index between 27 and 45
You will not qualify if you...
- Diabetes
- Chronic use of any antidiabetic medications
- Any unstable medical condition
- Use of steroids or daily use of NSAIDS
- History of chronic inflammatory conditions
- Use of anticoagulants
- Contraindications to the use of mirabegron or tadalafil
- Any condition deemed risky by the study physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Kentucky
Lexington, Kentucky, United States, 40536
Actively Recruiting
Research Team
Z
Zach Leicht
CONTACT
P
Philip Kern, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here